Sanofi, Pfizer, and others are developing therapies for the Acquired Hemophilia A treatment Acquired Hemophilia A Emerging therapies such as - BBM-H901, ISU304, TU7710, BE-101, REGV131 ...

Alnylam Pharmaceuticals has had a lot of excitement this year, with more good news potentially on the way. Summit Therapeutics could keep its momentum going with positive clinical results for cancer ...

Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

Hemophilia is a rare genetic condition that prevents your blood from clotting and can lead to bleeding problems. People with hemophilia can have bleeding episodes that happen without trauma and ...

Sanofi acquired the drug when it bought Bioverativ in 2018 for $11.6 billion, and the company has previously said it thinks it has the potential to become a $2 billion-a-year blockbuster.

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, and are hoping that a newly-approved long-acting drug can ...

Sanofi is harnessing the power of pop music to boost awareness of the experience of living with Type 1 diabetes. The French drugmaker has sponsored the formation of a new girl group, dubbed 1Type ...

CFOTO / Future Publishing via Getty Images A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial.

Sanofi’s U.S.-listed shares plunged more than 6% by 09:50 GMT, while Regeneron plummeted over 18%. Advertisement: High Yield Savings Offers Earn 4.10% APY** on balances of $5,000 or more ...

The Hemophilia B treatment landscape is entering a new era, marked by disruptive innovation, curative potential, and renewed global attention. Once viewed as a lifelong burden requiring constant ...